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VEGFa b s t r a c t
Myocardial infarction remains one of the top leading causes of death in the world and the damage sus-
tained in the heart eventually develops into heart failure. Limited conventional treatment options due to
the inability of the myocardium to regenerate after injury and shortage of organ donors require the devel-
opment of alternative therapies to repair the damaged myocardium. Current efforts in repairing damage
after myocardial infarction concentrates on using biologically derived molecules such as growth factors
or stem cells, which carry risks of serious side effects including the formation of teratomas. Here, we
demonstrate that synthetic glycosaminoglycan (GAG) mimetic peptide nanofiber scaffolds induce neo-
vascularization in cardiovascular tissue after myocardial infarction, without the addition of any biologi-
cally derived factors or stem cells. When the GAG mimetic nanofiber gels were injected in the infarct site
of rodent myocardial infarct model, increased VEGF-A expression and recruitment of vascular cells was
observed. This was accompanied with significant degree of neovascularization and better cardiac perfor-
mance when compared to the control saline group. The results demonstrate the potential of future clin-
ical applications of these bioactive peptide nanofibers as a promising strategy for cardiovascular repair.
Statement of Significance
We present a synthetic bioactive peptide nanofiber system can enhance cardiac function and enhance
cardiovascular regeneration after myocardial infarction (MI) without the addition of growth factors, stem
cells or other biologically derived molecules. Current state of the art in cardiac repair after MI utilize at
least one of the above mentioned biologically derived molecules, thus our approach is ground-breaking
for cardiovascular therapy after MI. In this work, we showed that synthetic glycosaminoglycan (GAG)
mimetic peptide nanofiber scaffolds induce neovascularization and cardiomyocyte differentiation for
the regeneration of cardiovascular tissue after myocardial infarction in a rat infarct model. When the pep-
tide nanofiber gels were injected in infarct site at rodent myocardial infarct model, recruitment of vascu-
lar cells was observed, neovascularization was significantly induced and cardiac performance was
improved. These results demonstrate the potential of future clinical applications of these bioactive pep-
tide nanofibers as a promising strategy for cardiovascular repair.
 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
Cardiovascular diseases constitute one of the major life threat-
ening diseases and are among the leading causes of morbidity and
mortality worldwide [1]. The prevailing cause of heart failure is the
death of heart muscle tissue. This irreplaceable cardiomyocyte loss
caused by arrested blood and oxygen flow to the heart is detrimen-
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tion and inevitable progression to heart failure [2]. Current treat-
ments for salvaging the jeopardized myocardium include
pharmacological therapy and percutaneous coronary intervention
or coronary artery bypass surgery. The limited efficiency of current
medical treatments might result in final stage heart failure, and
such heart failure patients require heart transplantation, which
has limited availability, or the support of ventricular assisted
devices, which have limited efficacy [3]. These limitations plum-
met the patient’s odds of survival and have led to the development
of novel therapeutic strategies such as regenerative medicine and
tissue engineering approaches for the repair of damaged myocar-
dial tissues.
Induction of angiogenesis is a vital mechanism that may allevi-
ate heart dysfunction after myocardial infarction (MI). Increased
vascularization and oxygen supply to the affected ischemic area
can reduce the degree of cardiomyocyte apoptosis and fibrosis
[4,5]. It is also essential to prevent the transition of infarction to
heart failure by providing long term left ventricular remodeling.
Pro-vascularization signals including biomolecules such as extra-
cellular matrix elements (e.g. collagen, elastin, laminin and fibro-
nectin), growth factors (e.g. VEGF and FGF2) and GAGs (e.g.
heparan sulfate and chondroitin sulfate), make up the structural
framework that regulates the behavior of vascular cells (i.e.
endothelial and smooth muscle cells) in order to establish stable
and functional vascular networks [6].
To date, several strategies have been tested including using
cytokines to modulate inflammation, introducing angiogenic
growth factors and transplantation of stem cells within various
matrices [7–9]. Previous studies also demonstrated the potential
of using heparin to deliver growth factors. Heparin preserves
growth factors in their active form by protecting them from prote-
olysis, and enhances the growth factors’ affinity to their respective
receptors, enabling consistent release of growth factors for an
extended period and optimizing their local concentration [10–
16]. The ability of heparin to bind to several angiogenesis promot-
ing growth factors, such as VEGF and FGF2, chemokines and cell
adhesion molecules via specific electrostatic interactions mediated
by their heparin binding domains or sulfated sequences have pre-
viously been identified. This binding boosts cell signaling, inducing
the formation of new blood vessels [17,18]. On the other hand, the
use of heparin in tissue engineering applications could trigger
immune reactions due to its animal origin [19].
Supramolecular scaffolds formed by self-assembling peptides
could address unmet needs of cardiac regenerative medicine by
providing a structural and functional recapitulation of native tissue
elements. Their biocompatibility and versatility for attachment of
discrete bioactive chemical groups make peptide based scaffolds
suitable for various tissue engineering applications [20–22].
Molecular stacking of these motifs through non-covalent interac-
tions gives rise to the formation of high-aspect-ratio nanofibers
at physiological conditions. These nanofibrous scaffolds can have
the advantage of slow degradation, hypo-immunogenicity, and
suitability for sustained release of specific growth factors immobi-
lized through covalent bonding. Recently, multidomain VEGF
mimetic peptides have been shown to promote an increase in
the microvessel density in an in vivo model in which hydrogels
were subcutaneously injected to the animals [23]. In another
study, nanofibers presenting VEGF-mimetic peptide at high density
were shown to induce phosphorylation of VEGF receptors and pro-
mote proangiogenic behavior in endothelial cells [24]. In a model
of acute myocardial infarction, significant preservation of hemody-
namic functions was demonstrated after injection of heparin bind-
ing self-assembling peptide nanofibers, which were capable of
binding to VEGF and bFGF [25]. Other studies also used injectable
in situ self-assembling peptide gels to recruit endogenousendothelial and smooth muscle cells and to stimulate angiogenesis
by slow release of angiogenic factors [26,27].
Recently, we have developed a GAG mimetic peptide nanofiber
scaffold that interacts with endogenous growth factors and induces
angiogenesis without the addition of external growth factors or
other supplements [6,28]. Through an innovative design, the GAG
mimetic peptide amphiphiles (PA) were decorated with a sul-
fonate, hydroxyl and carboxylic acid groups in order to mimic hep-
aran sulfate glycosaminoglycans, which are fundamental
constituents of the extracellular matrices of many tissues and
known to regulate growth factor binding and distribution [29]. In
addition to VEGF, GAG mimetic nanofibers were demonstrated to
bind to other angiogenesis related growth factors including hepa-
tocyte growth factor (HGF) and fibroblast growth factor-2 (FGF-
2) [6,28].
Here, we show that the injection of this previously described
angiogenic GAG mimetic peptide nanofibers led to better cardiac
function via preservation of more cardiac muscle and formation
of new blood vessels after MI in a rat cardiac infarct model. Cardiac
functional parameters were monitored through echocardiography
and hemodynamics and cellular level remodeling was assessed
through histological and immunofluorescence assessment. In addi-
tion to in vivo MI model, adhesion and differentiation of cardiomy-
oblast cells were studied in vitro.2. Materials and methods
2.1. Materials
All 9-fluorenylmethoxycarbonyl (Fmoc) and tert-
butoxycarbonyl (Boc) protected amino acids, lauric acid, [4-[a-(2
0,40-dimethoxyphenyl) Fmoc-aminomethyl] phenoxy]
acetamidonorleucyl-MBHA resin (Rink amide MBHA resin) and 2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluo-
rophosphate (HBTU) and diisopropylethylamine (DIEA) were pur-
chased from NovaBiochem, Merck and ABCR. The other chemicals
for peptide synthesis were analytical grade and purchased from
Fisher, Merck, Alfa Aesar, or Sigma Aldrich. All other materials used
in this study were purchased from Sigma–Aldrich, Invitrogen, Bio-
Rad, Fisher and Merck.2.2. Synthesis and characterization of peptide amphiphiles
PA molecules were synthesized by using solid phase peptide
synthesis method with Rink amide MBHA resin. For coupling of
amino acids, 1.95 equivalents of HBTU, 3 equivalents of DIEA and
1 equivalent of starting resin were used with 2 equivalents of
amino acid in 10 mL of dimethylformamide (DMF). Coupling of
each amino acid takes 2 h and Fmoc removal was performed with
20% (v/v) piperidine/dimethylformamide solution for 20 min. Lau-
ric acid addition was performed similarly to amino acid coupling
except that coupling time was 4 h. In order to acetylate the free
amine groups after each coupling step, 10% (v/v) acetic anhy-
dride–DMF solution was used after each coupling. Dichloro-
methane (DCM) and DMF were used for washing steps. The p-
sulfobenzoic acid addition to e-amine of lysine was done after
cleavage of Mtt protecting group of Fmoc-Lys(Mtt)-OH residue
with 5% of cleavage cocktail in DCM 3 times for 5 min. Peptide
cleavage from the resin and deprotections were carried out with
95% cleavage cocktail (95:2.5:2.5 trifluoroacetic acid (TFA): triiso-
propylsilane (TIS):water) for 2 h at room temperature. Excess TFA
was removed by rotary evaporation. Remaining PA solution was
precipitated in ice-cold diethyl ether overnight at 20 C. Centrifu-
gation was used to collect the precipitate and ultrapure water was
used to dissolve the pellet. The solution was frozen at 80 C and
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Agilent 6530 quadrupole time of flight (Q-TOF) mass spectrometry
with electrospray ionization (ESI) source equipped with reverse-
phase analytical high performance liquid chromatography (HPLC)
with Zorbax Extend-C18 2.1  50 mm column for basic conditions
and Zorbax SB-C8 4.6  100 mm column for acidic conditions. To
purify the PA molecules and remove residual TFA, preparative
HPLC system (Agilent 1200 series) was used for negatively charged
PAs and 0.1 M HCl was used for positively charged PAs. Dialysis
was used as a further purification method for the positively
charged PAs. After purification, PA molecules were lyophilized.2.3. Nanofiber formation and characterization
Solutions were prepared by dissolving PAs in sterile double dis-
tilled water, and their pH values were adjusted to 7.4. GAG
mimetic nanofibers were formed by mixing two PAs with different
molar ratios to have different charge combinations. To form GAG
mimetic nanofibers at pH 7.4, GAG-PA and K-PA molecules were
mixed at 1:2 molar ratio, respectively. Control nanofiber group
was prepared by mixing at 1:2 molar ratio of K-PA and E-PA,
respectively.2.3.1. Circular dichroism analysis
CD (JASCO J815 CD) was used to analyze secondary structures of
PAs. GAG-PA and K-PA as GAG mimetic nanofiber and E-PA and K-
PA as control nanofiber group were mixed at a concentration of
2  104 M. Secondary structures of individual PA were also ana-
lyzed at 2  104 M concentration. Scanning was done between
190 nm and 300 nm using a digital integration time of 1 s, a band-
width of 1 nm and with standard sensitivity. Molar ellipticity was
calculated with the data obtained from measurements.2.3.2. Mechanical characterization of the PA hydrogels
An oscillatory rheometer (Anton Paar Physica RM301) operating
with a 25 mm parallel plate configuration at 25 C was used to
investigate the mechanical properties of GAG-PA/K-PA gel.
10 mM GAG-PA and K-PA with a total volume of 250 lL were
loaded on the center of the plate and measurement was done with
0.5 mm gap distance, 100–0.1 rad/s angular frequency and 0.1%
shear strain. Similarly, E-PA with K-PA at 10 mM concentration
with a total volume of 250 lL was prepared to analyze mechanical
properties of resulting gel.2.3.3. Scanning electron microscopy and transmission electron
microscopy imaging
Morphological properties of the GAG mimetic nanofibers and
control nanofibers were observed with scanning electron micro-
scopy (SEM, FEI Quanta 200 FEG). GAG mimetic nanofiber was
formed by mixing 10 mM GAG-PA and K-PA and control nanofibers
were formed by mixing 10 mM K-PA and E-PA, allowing gel forma-
tion for 10 min followed by serial ethanol dehydration steps. After
gradual ethanol dehydration, hydrogels were dried by using critical
point dryer (Tousimis, Autosamdri-815B, Series C critical point
dryer) and coated with 5 nm Au/Pd before imaging.
Nanofibers were imaged by transmission electron microscopy
(TEM) (FEI Tecnai G2 F30 TEM). For sample analysis, 1 mM GAG-
PA was mixed with 2 mM K-PA (Control nanofibers were prepared
by mixing 1 mM K-PA with 2 mM E-PA in equal volumes) in equal
volumes on a 200-mesh carbon TEM grid for 1 min followed by
2 wt% uranyl acetate staining for 40 s and drying under flow hood.
TEM images were acquired at 300 kV.2.4. Myocardial infarction model and GAG mimetic nanofiber
treatment
All animal procedures were approved by the National Univer-
sity of Singapore, Institutional Animal Care, and Use Committee.
Male Wistar rats (250–350 g) were anaesthetized using inhalation
of 2% isoflurane and oxygen. Electrocardiography (ECG) was done
1 week before surgery to monitor the heart function. The chest cav-
ity was opened through mid-thoracotomy. The pericardium was
opened and the heart was exposed for sham groups (n = 15). For
the saline (n = 15), GAG mimetic nanofiber treated groups
(n = 15) and control nanofiber treated group (n = 15), myocardial
infarction was created by ligation of the left descending coronary
artery with a 7–0 suture. Ischemia assessment was done by the
immediate observation of myocardial blanching and alterations
in the ECG. Saline or PA solutions (GAG mimetic nanofiber as a
mixture of GAG-PA and K-PA, control nanofiber as a mixture of
E-PA and K-PA) (total volume = 100 mL) were injected at 4 different
sites (25 mL per site). After treatment, the chests were closed fol-
lowed by closing the muscle layer and skin layer. ECG was done
to monitor the post-surgery heart function. The rats were fre-
quently monitored and allowed to recover in a small animal inten-
sive care unit.
2.5. Echocardiography and hemodynamic measurement
Echocardiography was performed at day 0 and day 31 post-
operatively and measured by using the Vivid 6 Dimension ultra-
sound system (General Electric Vingmed, Horten, Norway)
equipped with the broadband 10S transducer. Following anesthe-
sia with isoflurane (5%) and oxygen (95%), EchoPacTM software
was used to measure the parameters such as Ejection Fraction
(EF), Fractional Area Change (FAC), Left-Ventricular (LV) internal
dimension in systole and diastole, End-Systolic Volume (ESV) and
End-Diastolic Volume (EDV).
The hemodynamic analysis was performed at 4 weeks post
operatively immediately prior to sacrifice using a pressure-
volume catheter (SPR-838NR, Millar Instruments, Houston, TX).
The catheter was inserted into the apex of the LV. The catheter
was stabilized for 15 min and then pressure-volume wave forms
were recorded using a multiple recording systems. Hemodynamic
data was analyzed using Lab chart 6.2 software (AD Instruments,
Australia). The hemodynamic analysis was performed and inter-
preted by researchers blinded to the treatment arms.
2.6. Histological analysis
The rats were sacrificed after the final echocardiography and
the hearts were excised and cut into two equal transverse slices
(n = 6). The lower slice was embedded in OCT while the upper slice
was paraffin embedded. Heart sections of 5 mm thickness on glass
slides. The sections were first deparaffinized in BondTM Dewax Solu-
tion and then rehydrated through 100% ethanol to 1 BondTM Wash
Solution. They were stained with either Masson Trichrome or
Hematoxylin and Eosin according to the manufacturer’s protocol.
The hematoxylin and eosin stained heart sections were analyzed
to measure the degree of infarct size and area and to investigate
the general tissue architecture. The LV slices from each heart were
digitized using (Leica) and then analyzed by Image J software (NIH,
Bethesda, Maryland) in a blinded manner. Briefly, the length of the
entire free wall and the portion occupied by the infarct scar (both
obtained at the midwall level) were measured, and the degree of
the infarct size was estimated as the ratio between infarct scar
length and length of the entire free wall and expressed as a per-
centage of the entire free wall. For infarct area measurement, both
the infarct area and the total LV area were manually traced from
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expressed as a percentage was calculated by dividing the infarct
area to total LV area and multiplying by 100.
2.7. Capillary density and VEGF expression analysis
The heart sections were stained with rat endothelial cell
antigen-1 (RECA-1) (Serotec, Puchheim, Germany) and alpha-
smooth muscle actin (alpha-SMA) (Sigma, Missouri, USA) to ana-
lyze the arterial density. Briefly, the frozen slides were fixed in
chilled 10% neutral buffered saline for 10 min at room tempera-
ture. After washing with 1X TBS-T, the slides were blocked with
10% goat serum for 30 min. The primary antibodies, RECA-1
(1:50) and alpha-SMA (1:100) were incubated overnight at 4 C.
After washing, secondary antibodies, Alexa-fluor 594 (1:500) and
488 (1:1000) were applied. The nuclei were then counterstained
with VectashieldTM Hard Set mounting medium with DAPI. The
RECA-1 and alpha-SMA positive vessels in 5 randomly selected
fields were evaluated in the infarct zones and peri-infarct zones.
The capillary and arterial densities were quantified in a blinded
manner and the data were presented as the mean number of ves-
sels per 200 magnification field. VEGF (Abcam, USA) was stained
using deparaffinized tissues that were treated with the same way
as mentioned above at a working dilution factor of 1:100.
2.8. Cell culture and maintenance
H9C2 cells derived from embryonic rat ventricle were a kind gift
from Gazi University, Ankara, Turkey. Cells were cultured in a
humidified, 37 C, 5% CO2 incubator using 75 cm2 polystyrene cell
culture tissue flasks containing High Glucose Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 15% (v/v) fetal bovine
serum (FBS), 1% (v/v) penicillin/streptomycin (P/S) and 4 mM L-
glutamine. Passaging of cells was carried out at cell confluency
between 50 and 60%, using trypsin/EDTA. Cells were diluted 1:4
for subculturing. Differentiation induction was carried out after
cells became 80% confluent by adding high glucose DMEM supple-
mented with 1% (v/v) FBS, 1% (v/v) penicillin/streptomycin and
10 nM retinoic acid (RA, Sigma–Aldrich). In all experiments, the
medium was changed in every 2 days.
2.9. In vitro cell culture studies
In vitro tests were carried out on GAG mimetic nanofiber or
Control nanofiber coated tissue culture plates and cover slips
unless otherwise mentioned. The coating was done by mixing
PAs in equal volume at 1 mM GAG-PA and 2 mM K-PA concentra-
tion after pH adjustment and sonication. Similarly, control nanofi-
bers were prepared by mixing 1 mM K-PA and 2 mM E-PA in equal
volume. Before coating process, solutions were sterilized under UV
for at least 1 h. Gel formation was achieved at 37 C for 30 min and
drying was performed under laminar flow hood overnight. Before
experiments, dried plates were further sterilized under UV light
for 1 h and washed with 1 PBS to remove unbound nanofibers.
Cell viability on the surface of nanofibers was tested with Ala-
mar Blue viability assay. In this experiment, 3 different charges
were tested and negatively, neutral and positively charged combi-
nations were formed by mixing GAG-PA (1 mM) and K-PA at vary-
ing molar ratios 1:2, 1:3 and 1:4, respectively. H9C2 cells were
seeded in 96-well plates at a density of 5  103 cells/well. After
24 h of standard incubation, Alamar Blue reagent was diluted
1:10 with serum-free medium and replaced with standard med-
ium. After subsequent 4 h of incubation, absorbance was measured
using microplate reader at 570 nm and 600 nm background. We
continued with 1 charge combination (1:2 ratios) for further
experiments.For cell adhesion experiments, cells were incubated for 1 h in
serum free DMEM medium supplemented with 4 mg/mL Bovine
Serum Albumin (BSA) and 50 mg/mL cyclohexamide at standard
culture conditions before seeding. After 1 h, cells were removed
from tissue culture plate by trypsinization and seeded onto the
coated 96-well plates at a density of 5  103 cells/well. After 2 h
of incubation in serum-free medium at standard culture condi-
tions, Calcein AM (Invitrogen) staining (2 lM) was performed for
40 min according to the manufacturer’s instructions. Cell adhesion
was quantified directly by counting the number of cells using
Image J (NIH) program from the images taken with a Zeiss Axio-
scope fluorescent microscope. Images were taken from 4 to 5 dif-
ferent locations per well, and the experiment was carried out
with n = 4. Results were then normalized to TCP.
The proliferation of cells on GAG mimetic nanofiber coating was
assessed using BrdU assay after 72 h. Cells were seeded onto PA
coated wells (1:2 molar ratio) and tissue culture plates at a density
of 3  103 cells/well. Cells were incubated in standard cell culture
conditions for 72 h. 2 h prior to the experiment, cell medium was
replaced with 10 mM BrdU labeling solution-containing standard
maintenance medium. At the end of incubation, BrdU incorpora-
tion assay was performed according to manufacturer’s instruc-
tions. Briefly, cells were fixed with FixDenat for 30 min and anti
BrdU-POD solution was added into wells. Following 90 min of
incubation and tapping, substrate solution was added into wells
and proliferation rates of the cells were quantified by measuring
absorbance (370 nm, with 492 nm reference wavelength) with a
microplate reader (Spectramax M5, Molecular Devices).
2.10. Gene expression analysis
Quantitative RT-PCR (qRT-PCR) was used for gene expression
analysis. Total RNA was isolated from cells, which were incubated
in differentiation medium for 7–10 days, using TRIzol (Invitrogen)
according to manufacturer’s instructions. Nanodrop 2000 (Thermo
Scientific) was used to assess yield and purity of extracted RNA.
Primer sequences were designed using Primer 3 software. The
reaction efficiencies for each primer set were evaluated with a
standard curve using 2-fold serial dilutions of total RNA. cDNA syn-
thesis from RNA and qRT-PCR were performed using SuperScript III
Platinum SYBR Green One-Step qRT-PCR Kit (Invitrogen) according
to manufacturer’s instructions. Ventricular myosin light chain-2
(Mlc-2v) and Myogenin genes’ expression patterns were analyzed
at day 0, 3 and 4. Primer sequences are shown in Table S1. Reaction
conditions were briefly as follows: 55 C for 5 min, 95 C for 5 min,
40 cycles of 95 C for 15 s, 60 C for 30 s, and 40 C for 1 min, fol-
lowed by a melting curve to confirm product specificity. For anal-
ysis of the expression data, primary gene expression data were
normalized by the expression level of GAPDH. A comparative Ct
method was used to analyze the results. Gene expression was nor-
malized to GAPDH and uncoated surfaces. For VEGF and Ang-1 tis-
sue expression, RNA was extracted from the heart tissues using the
RNeasy Fibrous Tissue Kit. cDNA synthesis was performed using
QuantiTect Reverse Transcription Kit (QIAGEN, Hilden, Germany).
Real Time PCR was done using BioRad CFX Thermal Cycler to check
on the expression of VEGF and Ang-1. The Taqman VEGF and Ang-1
primers were purchased from Life Technologies, USA.
2.11. Immunocytochemistry
Cardiac Troponin T staining was utilized as a marker of car-
diomyocyte differentiation. H9C2 myoblast cells were seeded onto
PA coated surfaces and glass surface (15 mm) at a density of
1.5  104 cells/well. Differentiation was induced after reaching
confluency. The medium was changed every day. For immunocyto-
chemistry, cells were fixed in 4% (v/v) paraformaldehyde/PBS for
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reduce nonspecific binding, samples were incubated with 3% (w/v)
bovine serum albumin/PBS blocking reagent for 2 h and treated
with 1:200 diluted Cardiac Troponin T primary antibody (Ms.
Ab33589) overnight at 4 C, and were incubated with Alexa Fluor
488 goat anti-mouse secondary antibody at 1:300 dilution for 1 h
at room temperature. Extensive washing with 1 PBS was per-
formed between each step. All samples were counterstained with
1 lM TO-PRO-3 (Invitrogen) and 1:500 diluted phalloidine in 1
PBS for 20 min at room temperature and mounted with Prolong
Gold Antifade Reagent (Invitrogen). Samples were imaged by using
a confocal microscope (Zeiss LSM510).2.12. Statistical analysis
In vivo data are presented as the mean ± standard deviation and
n = 15 for all groups. One-way analysis of variance (ANOVA) fol-
lowed by Tukey-HSD post-hoc multiple comparison tests was uti-
lized for comparison of multiple groups using Graphpad prism
software. The difference was considered statistically significant at
a p-value of <0.05.
The quantitative in vitro results are presented as a mean ± stan-
dard error of the mean (SEM). Statistical analysis was carried out
by means of one-way analysis of variance (ANOVA) with Tukey
posttest and student t-test unless otherwise mentioned. A p-
value of less than 0.05 was considered statistically significant. All
the experiments were independently repeated 3 times.3. Results
3.1. Formation and characterization of self-assembled peptide
nanofibers
Modulation of cardiovascular cell fate through the extracellular
matrix (ECM) mimicking smart biomaterials is an emerging strat-
egy for developing efficient regenerative cardiovascular therapies.
Self-assembling PA molecules decorated with biologically active
groups that mimic the structure of heparan sulfate were synthe-
sized and utilized to generate a nanofibrous microenvironment
that can mimic the structural and functional aspects of the native
myocardial extracellular matrix. Since angiogenesis is one of the
crucial factors for the functional restoration of the myocardium,
GAG mimetic peptide nanofibers were assessed for their ability
in protecting the ischemic myocardium due to their growth factor
binding capacities and angiogenic properties. The chemical struc-
tures of GAG peptide amphiphile, Lauryl-VVAGEGD-
K(p-sulfobenzoyl)-S-Am (GAG-PA) and oppositely charged
Lauryl-VVAGK-Am (K-PA) are shown in Fig. 1. To assess the effect
of the nanofibrous morphology, compared to the bioactivity caused
by mimicking heparan sulfate, we used non-bioactive nanofibers
(Control nanofibers) composed of E-PA and K-PA (Fig. 1). The PA
molecules were synthesized by using Fmoc solid phase peptide
synthesis, purified by preparative HPLC and analyzed by LC–MS
(Fig. S1). The self-assembly of the PAs into nanofibers was trig-
gered by mixing oppositely charged GAG-PA and K-PA as GAG
mimetic nanofiber group and E-PA with K-PA as Control nanofiber
group. Their abilities to form extended structures were analyzed
using circular dichroism (CD). The CD spectra of the PAs demon-
strated an ordered b-sheet secondary structure as the major struc-
tural component of the assembled nanofibers (Fig. 1B). Oscillatory
rheology measurements, which were performed to analyze the
mechanical properties of the peptide hydrogels formed by the
nanofibers, showed that the hydrogels exhibited storage moduli
between 5 and 6 kPa and loss moduli between 300 and 400 Pa at
10 mM concentration (Fig. 1C).SEM micrographs showed that the self-assembly of PAs gener-
ated porous nanofibrous networks, similar to native ECM
(Figs. 1D and S2). TEM images revealed that individual nanofibers
formed by self-assembly of oppositely charged PAs were uniform
in diameter, which was 7.5 nm (Figs. 1E and S2).
3.2. Intramyocardial injection of GAG mimetic bioactive peptide
nanofiber improved cardiac function post-MI
In order to assess the effect of GAG mimetic peptide nanofibers
on cardiac function post-MI, GAG mimetic or Control nanofibers
were injected intramyocardially to the infarct site in rat myocar-
dial infarction model. Echocardiography was used to assess the
cardiac function before and after formation of infarct and injection.
30 days post-treatment echocardiography analysis showed that
the GAG mimetic nanofiber treated group attenuated left ventricu-
lar (LV) remodeling, which is essential to prevent heart failure.
Ejection fraction (EF) was 37.28 ± 10.32% in the saline group, com-
pared to 71.82 ± 12.56% in the GAG mimetic nanofiber treated
group. The GAG mimetic nanofiber treated group also showed
improvement in fractional area change (FAC) when compared to
the saline group. FAC was 41.86 ± 7.75% in the saline group and
58.08 ± 5.13% in the GAG mimetic nanofiber treated group. The left
ventricle internal dimension during diastole (LVIDd) was
9.78 ± 0.17 mm in the saline group versus 8.51 ± 0.31 mm in the
GAG mimetic nanofiber treated group. The left ventricle internal
dimension during systole (LVIDS) was 6.91 ± 0.27 mm in the saline
treated group versus 5.46 ± 0.53 mm in the GAGmimetic nanofiber
treated group (Fig. 2). GAG mimetic nanofiber treated group also
displayed improved end-systolic volume (ESV) and end-diastolic
volume (EDV) with a value of 0.17 ± 0.05 mL and 0.62 ± 0.06 mL,
respectively. For left ventricular posterior wall at systole (LVPWs)
and diastole (LVPWd), the value of 2.17 ± 0.62 mm and
1.63 ± 0.60 mm was observed respectively. A significant difference
was found when results were compared with saline treated groups.
The control nanofiber treated group also showed significantly
improved cardiac performance because of partial bioactivity due
to chemically functional groups (Fig. 2).
3.3. GAG mimetic bioactive peptide nanofiber treatment resulted in
significant improvement in cardiac output, LV pressure, and
contractility
The hemodynamic analysis was carried out in all four groups
(sham, saline and Control nanofiber and GAG mimetic nanofiber
treated group) and the data is shown in Table 1. No difference
was observed in body weight and heart rate at 30 days post-
treatment between all four groups. GAG mimetic nanofiber
injected group and control nanofiber group showed statistically
significant increase in contractility index, cardiac output and mean
LV pressure when compared to saline treated group (p < 0.05).
3.4. Bioactive GAG mimetic nanofiber hydrogel injection preserved
cardiac muscle and prevented infarct expansion
At 4 weeks post-treatment, cross-sections at the mid papillary
muscle level showed transmural infarctions in both saline and pep-
tide nanofiber treated groups. Semi quantitative analysis demon-
strated that the infarct size and the infarct area were smaller in
the GAG mimetic nanofiber treated group (43 ± 6.04 and
23 ± 5.21, respectively) compared to the saline treated group
(62 ± 7.43 and 41 ± 5.12, respectively) and Control nanofiber trea-
ted group (51 ± 8.26 and 37 ± 4.78, respectively) (Figs. 3 and S7).
The differences between GAG mimetic nanofiber and control
groups were statistically significant. A higher degree of surviving
cardiomyocyte tissues in the peri-infarct segment was observed
Fig. 1. Chemical structures and characterization of peptide amphiphile molecules and nanofibers. Chemical structures of (A) GAG-PA, K-PA, and E-PA. Characterization of PAs:
(B) circular dichroism spectra of PAs showing the b-sheet structure of GAG mimetic nanofibers (GAG-PA + K-PA mixture) and control nanofibers (E-PA + K-PA mixture), (C)
rheology measurement results showed gelation confirmed by higher storage modulus than loss modulus and (D) SEM (Scale bar = 4 mm) and (E) TEM micrographs of GAG
mimetic nanofibers. Micrographs revealed the nanofibers forming a fibrous network that mimic the native nanofibrous ECM architecture (Scale bar = 100 nm).
Fig. 2. Injection of GAG mimetic bioactive peptide nanofiber improved cardiac function at 30 days after MI. Echocardiography analysis at 30 days post-treatment revealed
that GAG mimetic nanofiber treated group resulted in better preservation of left ventricular function in comparison to saline treated group. (A) Left ventricular internal
dimension at systole (LVIDs) and diastole (LVIDd), (B) end diastolic volume (EDV) and end systolic volume (ESV), (C) ejection fraction (EF) and fractional area change (FAC),
(D) left ventricular posterior wall at systole (LVPWs) and diastole (LVPWd). (E) Hydrogel injection significantly enhanced the% Fractional shortening (FS). Data are means ± SD
(n = 15 per group). (*p < 0.05 and ****p < 0.0001 compared to saline treated the group as determined by one-way ANOVA and Tukey’s comparison test.)
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resulting in increased wall thickness when compared to the saline
treated group. In addition, Masson’s trichrome staining of the
myocardial tissues demonstrated a smaller degree of fibrosis
throughout the left ventricle of GAG mimetic nanofiber treated
group compared to saline and Control nanofiber treated groups.
Pink muscle fibers can be distinguished from blue stained ECM
(Fig. 3).3.5. Bioactive GAG mimetic peptide nanofiber treatment promoted
arteriogenesis after MI
The GAG mimetic nanofiber treatment resulted in a signifi-
cantly higher number of stained capillaries compared to saline
and Control nanofiber groups in both infarct and peri-infarct areas
(Fig. 4A). GAG mimetic nanofiber hydrogel injected group showed
a 2.7-fold increase in the number of smooth muscle actin (SMA)
Table 1
GAG mimetic nanofiber treatment showed improvement in cardiac output, LV pressure, and contractility. *p < 0.05 versus saline treated group.
Sham Saline Control nanofiber group GAG mimetic nanofiber group
Body Weight (g) 507 ± 33.21 462 ± 35.52 476 ± 32.54 502 ± 31.68
Heart rate (bpm) 183.2 ± 40.05 171.3 ± 53 180.67 ± 37.7 190.2 ± 12.35
Contractility Index (1/S) 84 ± 4.6 61.2 ± 3.7 75.21 ± 4.1* 79.5 ± 3.9*
Cardiac Output 40.2 ± 13.8 28.6 ± 10.5 44.35 ± 7.13* 51.4 ± 6.3*
Mean LV Pressure 75.4 ± 9.2 50.8 ± 7.6 61.7 ± 4.8* 66.3 ± 7.5*
Maximum positive dp/dt 3071 ± 323.6 1832.2 ± 256.3 2264 ± 303.5* 2511 ± 307.1*
Maximum negative dp/dt 2440 ± 507.4 1529 ± 299.1 1856 ± 424.1* 2071 ± 275.5*
Fig. 3. Representative images of hematoxylin and eosin and Masson trichrome staining of the myocardial tissues at 4 weeks post-treatment showed decreased infarct
expansion in GAGmimetic nanofiber treatment group compared to Control nanofiber and saline treated groups. (Muscle fibers: Pink and ECM: blue). Scale bars, 500 mm for all
panels. Macroscan images of Masson trichrome shows the improvement. % Infarct size and area plot, data are means ± SD (n = 6 per group). (Statistical analysis was carried
out by one-way ANOVA and Tukey’s comparison test, where *p < 0.05, ***p < 0.001 and ****p < 0.0001).
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antigen-1 (RECA-1) positive vessels in the infarct area when com-
pared to the saline treated group (Fig. 4B). Also, GAG mimetic
nanofiber group showed a 4-fold increase of SMA and 1.9-fold
increase for RECA-1 in comparison to Control peptide group. Sim-
ilarly, in the peri-infarct area, GAG mimetic nanofiber treatment
resulted in an approximately 2.3-fold increase of SMA positive ves-
sels and a 1.8-fold increase of RECA-1 positive vessels when com-
pared to the saline treated group (Fig. 4C) whereas there is the 3.5-
fold difference in SMA and the 1.57-fold difference in RECA-1 pos-
itive vessels compared to Control nanofiber group. These results
showed that GAG mimetic nanofiber hydrogel increased arterio-
genesis in both infarct and peri-infarct area, significantly.
In addition to RECA-1 and SMA staining, we also investigated
gene expression of VEGF-A and Angiopoietin-1 (Ang-1) both of
which have important roles in angiogenesis and vascular develop-
ment. Results showed that there is a 12.3-fold increase in the
expression of VEGF-A in the GAG mimetic nanofiber treated groupwhen normalized to sham. There is 3.6 and 6.1-fold increase in sal-
ine and control nanofiber groups, respectively, yet the difference
between these groups and GAG mimetic nanofiber group is statis-
tically significant. In terms of Ang-1 expression, similar to VEGF-A
expression, there is a 6.02-fold increase in GAG mimetic nanofiber
group, which is significantly different than the control groups
(Figs. 5D and S6).
Notably, VEGF staining in tissue sections demonstrated the
enhanced level and localization of VEGF in both infarct and peri-
infarct area for GAG mimetic nanofiber treated groups compared
to saline treated, and Control nanofiber treated groups (Fig. 5).
3.6. GAG mimetic peptide nanofibers promoted adhesion and
proliferation of cardiomyocytes in vitro
In order to assess the effect of GAG mimetic nanofibers on the
cellular behavior of H9C2 myoblasts, derived from rat myocardia,
was investigated by culturing these cells on peptide nanofiber
Fig. 4. Representative immunostained images of cardiomyocytes with SMA positive vessels (green), RECA-1 positive vessels (red) and DAPI (blue). Intramyocardial GAG
mimetic nanofiber treatment showed an enhanced degree of arteriogenesis in both infarct and peri-infarct areas at 30 days after MI (scale bars = 100 mm for all panels). Data
are means ± SD (n = 6 per group). (Statistical analysis was carried out by one-way ANOVA and Tukey’s comparison test, where ****p < 0.0001).
Fig. 5. (A–C) Representative immunostained images of VEGF in both saline, Control nanofiber and GAG mimetic nanofiber treated tissues. Intramyocardial GAG mimetic
nanofiber treatment showed an enhanced degree of VEGF staining in both infarct and peri-infarct areas at 30 days after MI (scale bars = 100 mm for all panels, VEGF stained in
brown). (D) Cardiac tissue gene expression analysis of VEGF-A and Ang-1 (normalized to Sham group). Data are means ± SD (n = 6 per group), (Statistical analysis was carried
out by one-way ANOVA and Tukey’s comparison test, where ****p < 0.0001).
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system on cellular viability, GAG-PA and K-PA molecules were
mixed in different molar ratios to display positive, neutral and neg-
ative final charges on different wells. Viability of H9C2 cells was
analyzed by Alamar Blue assay after culturing on GAG mimetic
nanofibers for 24 h, and the results showed that peptide nanofibers
did not alter the viability of the cells compared to tissue culture
plate (TCP), and GAG/K-PA system is biocompatible with H9C2
cells at all three charge combinations (Fig. 6B). Investigation of cel-
lular morphology with an optical microscope showed that nativecell morphology of H9C2 cells was preserved on PA coated sur-
faces. In further experiments, molar ratios of mixtures were
adjusted to yield a system with a net negative charge, matching
the system utilized in our previous study on peptide-induced
angiogenesis [6].
We also investigated the initial adhesion behavior of H9C2 cells
on GAG mimetic nanofibers in the presence of bovine serum albu-
min (BSA) and the translation inhibitor cyclohexamide, which min-
imizes the interference of endogenous proteins with the adhesion
process. After 2 h of incubation, Calcein AM staining and quantita-
Fig. 6. Adhesion and in vitro biocompatibility analysis of GAG mimetic nanofiber and epitope free Control nanofiber group. (A) Fluorescent micrograph of adhered cells after
2 h of incubation in serum free adhesion medium. (B) The viability of H9C2 cells on peptide coated surface after 24 h. (C) The proliferation of cells analyzed by BrdU
incorporation, (D) Quantitative analysis of initial 2 h adhesion of cells to surfaces. Data are means ± SEM (*p < 0.05).
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adhered to the GAG mimetic nanofiber coated surface slightly
more than uncoated plates (Fig. 6A, D). The proliferation of H9C2
cells on GAG mimetic nanofibers was slightly less than these on
TCP, but the difference between the groups was not statistically
significant (Fig. 6C), as analyzed by BrdU assay. Control nanofibers
used as an epitope-free control group for the GAG mimetic nanofi-
bers did not support the growth and proliferation of cells in vitro
(Fig. 6B, C). Therefore, we did not include the epitope-free control
group in remaining in vitro experiments.
Effects of peptide nanofibers on the upregulation of the expres-
sion of specific cardiac marker genes were analyzed to understand
the commitment of progenitor cells into cardiomyocyte lineage
[30–32]. The H9C2 cells seeded on GAG mimetic nanofibers
showed higher expression of Mlc-2v, a cardiac specific marker
[32], than the cells grown on TCP at day 7. Expression started ear-
lier in cells cultured on peptide nanofibers compared to cells cul-
tured on TCP. We also analyzed the gene expression level at day
10 and observed increased expression of Mlc-2v on TCP, which
shows delayed differentiation of cells on TCP surfaces compared
to the GAG mimetic nanofibers (Fig. S3). There was no difference
in the expression of the skeletal muscle marker myogenin when
the experimental groups were compared (Fig. S3B).
We also investigated the expression of cardiac troponin T (cTnT)
protein, which an important cardiac-specific protein and plays a
role in cardiac muscle contraction and relaxation [33]. H9C2 cells
cultured in growthmedium does not exhibit cTnT staining although
they fuse with each other which is a typical myoblastic behavior
after a certain time of culture (Fig. S4C). However, after the cells
were cultivated in differentiationmedium for 10 days, cTnT protein
expression was observed on both GAG mimetic nanofiber coated
surfaces and TCP, and there was no difference between the groups
(Fig. S4A and B). Cardiomyocytes on GAG mimetic nanofibers also
exhibited sarcomeric organization, observed through phalloidin
staining. Likewise, SEM micrographs of cells after 10 days showed
the cardiomyocyte-like morphology of cells and further confirmed
the absence of long skeletal myotubes (Fig. S5).4. Discussion
One of the major goals of cardiac tissue engineering is to create
a favorable microenvironment for cells in ischemic regions, in
order to support the cells mechanically as well as guide them bio-
chemically by resembling the native extracellular niche [26,34].
Previous studies elaborated the structural resemblance of peptide
nanofibers with collagenous proteins found in the extracellular
matrix of many tissues such as collagen I, collagen III and fibrillin
whose diameters vary from 10 to 100 nm [35].
In this study, we demonstrated the potential of GAG mimetic
nanofibers in improving heart function by limiting the degree of
cardiac fibrosis and preventing negative remodeling in rodent MI
model as well as supporting the survival of cardiomyocytes. These
nanofibers exhibited b-sheet morphology, and electron microscopy
imaging showed that individual nanofibers formed a nanofiber net-
work that structurally resemblesmorphology of native ECM by pro-
viding mechanical support and instructive cues for cells. The
baseline elastic modulus for normal heart muscle was previously
shown to be around 18 ± 2 kPa and infarcted animals receiving no
treatment had stiffer tissue due to fibrosis [36]. Peptide nanofibers
in the range of 5–10 kPa canwithstand themechanical cycling since
they are mechanically compliant with the native tissue and break-
down of the gels during contraction and relaxation is not possible as
in the case of hydrogels with low mechanical strength.
Sonnenberg et al. recently used decellularized ECM-derived
platform with sulfated glycosaminoglycan content to deliver
HGF-1 into rat MI model and demonstrated improved fractional
area change and vascularization [37]. Despite its promise and good
results, harvesting enough quantity of autologous graft tissue
without compromising the donor-site is limited. In addition,
although allografts may eliminate such issue, they possess the risk
of severe immune response and have integration problems with
native tissue compared to autologous grafts [38].
On the other hand, synthetic biologically active peptide nanofi-
bers could be more advantageous in providing similar signals for
tissue regeneration due to their very low risk of immune response
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injection of bioactive GAG mimetic nanofibers resulted in
improved cardiac function and enhanced angiogenesis in the
infarcted left ventricle. Specifically, treatment with hydrogels
showed 69% improvement in ejection fraction and 35.9% improve-
ment in fractional shortening.
Interestingly, the positive effects seen after treatment with
bioactive GAG nanofibers on the cardiac function was also
observed to a certain degree with the control nanofibers. The favor-
able effects of the control nanofiber treatment could have been due
to the mechanical support and structural reinforcement provided
by the nanofiber in stabilizing the infarct wall and maintaining
the wall thickness. It was previously reported that passive struc-
tural enhancement alone cannot provide full therapeutic benefit
as a combination of both physical and biological activity are critical
[42]. Hence, it is possible that that the functional improvement
observed in this study may be a short term response.
On the other hand, increased angiogenesis via upregulation of
VEGF and Ang-1 post-MI by GAG mimetic nanofiber treatment
compared to control nanofiber group indicated that GAG mimetic
nanofiber treatment could be more advantageous in the long run
if they are able to sustain the degree of mature vasculature forma-
tion. This needs to be addressed further in a long term study of MI
models. In addition, a higher degree of surviving cardiomyocyte tis-
sues in the infarct area in the GAGmimetic nanofiber treated group
could result in increased wall thickness compared to saline treat-
ment, which alters the surrounding tissue properties and reduces
the wall stress. Less wall stress results in reduced after load and
end systolic volume, which is likely because there is significant dif-
ference in end LV diastolic volume and end systolic volume
between saline and nanofiber treated groups. This decrease in LV
wall stress is also thought to protect the vulnerable myocardium
from stress induced apoptosis and infarct expansion, thus prevent-
ing pathologic LV remodeling and decline in cardiac function [43].
It is important to stress that in addition to increasing only the
volume of an area similarly to other injectable gels, angiogenic
bioactivity of GAG mimetic nanofiber hydrogels is critical in induc-
ing angiogenesis, which ensures a steady supply of oxygen and
nutrients to the ischemic area. These peptide nanofibers were
recently used to transplant pancreatic islets and shown to improve
both viabilities of islets and number of intraomental vessels in dia-
betic rats [39]. Similarly, in this work, we observed improved car-
diomyocyte protection with reduced degree of fibrosis and a
significant increase in mature blood vessel formation.
In a previous study, Guo et al. showed improved cardiac func-
tion after delivering VEGF with self-assembling peptides [27].
Strikingly, in the present study, we observed same therapeutic
effects without any additional exogenous angiogenic growth fac-
tors. VEGF and Ang-1 genes are two of many that are turned on
to regulate blood vessel growth, and we observed the significantly
high level of endogenous VEGF-A and Ang-1 expression in GAG
mimetic nanofiber treated animals. This is also supported with
the histological staining that shows VEGF localization in infarct
and the peri-infarct area is higher in the GAG mimetic nanofiber
treated group compared to Control nanofiber and saline treated
ones. This confirms that the GAG mimetic nanofibers created a
supportive microenvironment by both increasing expression and
localization of endogenous growth factors in the infarct and peri-
infarct regions of the ischemic myocardium and promote recruit-
ment, retention, and maturation of vascular cells.
Immunostaining results also showed a higher degree of arterio-
genesis in animals receiving GAG mimetic nanofiber treatment,
which implied that the scaffold was able to recruit smooth muscle
cells in addition to endothelial cells, to form stable and functional
vascular networks (Fig. 4). Newly formed vessels help the restora-
tion of blood flow to prevent loss of cardiomyocytes and enhancecardiac performance, which is in good agreement with the Echo
results.
Survival of residual cardiomyocytes could be also supported by
increased expression of Ang-1. Ang-1 is known to be a critical gly-
coprotein that activates prosurvival pathways by binding to inte-
grin receptors of muscle cells and promotes survival [40].
Increased expression of Ang-1 in GAG mimetic nanofiber treated
group could be the reason of the prevention of cardiac myocyte
loss and retaining of contractility relative to the controls along
with its role in the angiogenesis. Also, increased VEGF expression
and localization in the ischemic area might contribute to the acti-
vation and migration of cardiac stem cell population to the affected
area to repair infarction [41]. Overall, GAG mimetic nanofibers
enabled cells to restore cardiac function and structure.
Some of the limitations in assessing the data of this study
include the use of an acute MI model whereby the treatment is per-
formed 30 min after the infarction was initiated. Acute MI models
are relevant to only a subgroup of patients in clinics since the
majority of the patients are chronic in nature. The work should
be also extended to chronic models in the future. In addition, the
period of investigation was 4 weeks and this turned out to be
insufficient to differentiate the full effect of the GAG mimetic and
control nanofiber treatment. The data, however, confirmed the
positive results of other studies on the use of hydrogels in MI mod-
els. While we saw the potential of GAG mimetic peptide nanofiber
in converting cardiomyoblasts to cardiomyocytes in vitro with the
model cell line, we did not observe the creation of new cardiac
muscle in the infarcted LV in this short term study of an acute
model. A chronic model and/or a longer term study of acute model
would be more appropriate in assessing this capability of GAG
mimetic nanofibers in vivo.
5. Conclusion
In summary, we present the efficacy and safety of the injectable
self-assembled GAG mimetic and control nanofibers in promoting
angiogenesis and cardiac regeneration after MI in the pre-clinical
small animal study. Both control and GAG mimetic nanofibers
improved cardiac function in the short term while GAG mimetic
nanofibers also increased vasculature via upregulation of VEGF-A
and Ang1. This system serves as a new generation biomaterial for
angiogenesis and tissue regeneration by avoiding the use of hep-
arin and exogenous growth factors. While the injected scaffolds
may provide localized regions for survival and organization of vas-
cular cells, further studies are necessary to assess if it is possible for
the scaffolds to be engineered to provide additional signals for
in vivo recruitment and maturation of cardiomyocytes or car-
diomyocyte progenitors as well. It is also crucial to determine
whether these microenvironments will not be proarrhythmic,
which will undermine the benefits of such treatment. The mecha-
nism of differentiation induction through GAG mimetic nanofibers
and affected signal pathways should also be deeply investigated.
With these follow up studies, the technology of using self-
assembled GAG mimetic peptide nanofibers in cardiac regenera-
tion has a high potential of being translated into clinics.
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